Streetbeat News

Earnings

KSS

Kohl's Corporation (NYSE:KSS) is anticipated to announce its Q4 earnings on March 12, 2024, with expectations of a profit of $1.28 per share compared to a loss of $2.49 per share in the previous year. Revenue is projected at $5.70 billion, slightly down from $5.78 billion. The company declared a quarterly dividend of 50 cents per share. Recent analyst ratings include a Market Perform from Telsey Advisory Group with a $25 target, a Neutral from Citigroup with a $27 target, an In-Line from Evercore ISI Group with a $24 target, and an Underperform from B of A Securities with a $22 target.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 2:50 pm

XOM

Benzinga's options scanner revealed significant options trading activity on Exxon Mobil (NYSE:XOM), with over 13 transactions totaling $421,036. Analysis of trading volumes and open interest suggests a focus on a price range between $105.0 and $125.0. The largest options trades indicate a bullish sentiment, despite the variety of puts and calls. Exxon Mobil, a leading oil and gas company, is currently trading at $108.55, with potential signs of approaching overbought territory. The anticipated earnings release is in 46 days.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 2:46 pm

Deep-pocketed investors have shown a bearish sentiment towards Zscaler (NASDAQ:ZS), with options activity indicating a divided mood: 46% bullish and 53% bearish. Notable options trades suggest a price target range of $150-$230. Zscaler, a SaaS firm specializing in cybersecurity, has seen its stock price decrease by 1.0% to $196.7. Analysts have set an average price target of $245.8, with ratings ranging from Equal-Weight to Buy. The next earnings report is expected in 80 days.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 2:46 pm

GDC

LDWY

MOMO

TEO

The article highlights five notable value stocks in the communication services sector, emphasizing their low P/E ratios as indicators of potential undervaluation. These stocks include Lendway, Telecom Argentina, KT, GD Culture Group, and Hello Gr, with recent earnings reports suggesting varied financial performance.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 2:45 pm

ALKS

INMD

KPRX

PROC

SYRS

The article identifies Kiora Pharmaceuticals, Procaps Gr, InMode, Alkermes, and Syros Pharmaceuticals as notable value stocks in the healthcare sector, based on their low P/E multiples. It provides recent earnings per share data for each company, indicating financial performance and potential risks associated with investing in value stocks.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 2:44 pm

CHCI

PMT

SEVN

SQFT

Benzinga Insights identifies 5 value stocks in the real estate sector with low P/E multiples, suggesting undervaluation. The stocks include Seven Hills Realty Trust (SEVN), Comstock Holding Co (CHCI), PennyMac Mortgage IT (PMT), Presidio Property Trust (SQFT), and Urban Edge Props (UE), each showing recent financial performance and dividend yields.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 2:39 pm

EQT

GNE

VTYX

U.S. stocks were lower on Monday, with the Dow Jones index falling over 150 points. EQT Corporation's shares dropped 8.4% after announcing a merger with Equitrans Midstream. Other notable declines include Ventyx Biosciences, MoneyLion Inc., Genie Energy Ltd., and several others, each falling due to various company-specific news such as clinical data reports, quarterly results, and strategic updates.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 2:37 pm

SLRN

Acelyrin Inc (NASDAQ:SLRN) announced positive results from its Phase 2b/3 trial of izokibep for Psoriatic Arthritis, meeting the primary endpoint with high statistical significance. The drug was well-tolerated, showing a favorable safety profile. Additionally, long-term data from a Phase 2b trial in hidradenitis suppurativa demonstrated no increased safety liability with longer-term treatment, with clinical improvements over time. SLRN shares rose 7.35% to $8.03.

Portfolio Pulse from Vandana Singh

March 11, 2024 | 2:32 pm

MNKD

MannKind Corporation (NASDAQ:MNKD) shares are in focus due to initial meal challenge data from INHALE-3, a Phase 4 clinical trial for inhaled insulin, showing promising results. The company also reported Q4 earnings of 2 cents per share with sales of $58.47 million, surpassing analyst estimates. CNBC's Jim Cramer discussed the stock, noting its potential for an earnings breakout. Analysts have a 12-month price target range of $6.50 to $7.50, with an average of $7.00. MannKind shares are currently down 8.35% at $4.82.

Portfolio Pulse from Erica Kollmann

March 11, 2024 | 2:28 pm

NLCP

NewLake Capital Partners, Inc. (NLCP) reported a 6.4% YoY increase in Q4 revenue and a 5.1% increase in full-year revenue for 2023, amidst a challenging cannabis industry environment. The company also announced a dividend increase and highlighted financial achievements including record revenue and AFFO. Additionally, NewLake invested in expanding a cultivation facility in Missouri and sold a facility in Massachusetts.

Portfolio Pulse from Jelena Martinovic

March 11, 2024 | 2:09 pm